Husam Younis, Chief Scientific Officer of Atrium Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 22, 2026, reporting a transaction in the company's common stock dated September 18, 2026.

Key Highlights

  • Reporting person: Husam Younis, serving as Chief Scientific Officer of Atrium Therapeutics, Inc.
  • Transaction date: September 18, 2026, involving common stock of Atrium Therapeutics, Inc. (NASDAQ:RNA)
  • Shares disposed: 11,216 shares of common stock were disposed of (transaction code F) at a price of $8.95 per share
  • Purpose of disposal: According to the filing, the shares were "withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units"
  • Remaining ownership: Following the transaction, Younis directly beneficially owned 41,441 shares of common stock

Atrium Therapeutics CSO Ownership After RSU Vesting Tax Withholding

According to the filing, the transaction recorded was a disposition coded "F," which the filing's footnote explains represents shares withheld by the issuer to cover tax withholding obligations arising from the vesting of restricted stock units. The disposal of 11,216 shares at $8.95 per share was not an open-market sale initiated by the reporting person, but rather a withholding action by Atrium Therapeutics, Inc. itself upon RSU vesting.

Husam Younis holds the title of Chief Scientific Officer at Atrium Therapeutics, Inc., a company whose ticker symbol appears in the filing as RNA, listed on NASDAQ. Following the September 18, 2026 transaction, Younis's direct beneficial ownership in the company's common stock stood at 41,441 shares, as reported in Table I of the filing. No derivative securities transactions were reported in Table II. The filing was signed by Brendan Winslow as Attorney-in-Fact on September 22, 2026, and was filed individually, not jointly with any other reporting person.

What Was Disclosed

The filing reported a single non-derivative transaction in which 11,216 shares of Atrium Therapeutics common stock were withheld at $8.95 per share for tax purposes upon RSU vesting, leaving Husam Younis with direct beneficial ownership of 41,441 shares.